Cognosetta Inc. is a pharmaceutical company dedicated to developing treatments for previously untreated hearing disorders. Our two main pipelines are focused on treatments for two of the most prevalent unmet hearing disorders in the United States, tinnitus and age related hearing loss.
At Cognosetta, we're developing small molecule and peptide drug candidates into FDA-approved medications for hearing and other neurological disorders.
Cognosetta is developing a first-in-market, brain-targeted pharmaceutical solution for treating tinnitus. Cognosetta has secured non-dilutive funds to support development. To complete foundational preclinical and clinical safety and dosing studies, we are currently seeking additional private investment.